Uncategorized Archives - Page 11 of 248

ThursdayMar 21, 2024 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss; Sets Stage for 8-week Diabetes and Weight Loss Animal Study

Lexaria, a global innovator in drug delivery platforms, highlighted results from its DIAB-A22-1 animal study, highlighting a 7% reduction in weight and a 19.9% reduction in blood glucose With this success, Lexaria looks to kick off its WEIGHT-A24-1 animal study to examine diabetes and weight loss effects of its patented DehydraTECH(TM)-processed GLP-1 drugs and DehydraTECH-processed CBD The study will comprise 12 arms and involve 72 animals. It will run for a total of 12 weeks This study will build on previous studies that evidenced DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue Lexaria Bioscience (NASDAQ:…

WednesdayMar 20, 2024 4:20 pm

420 with CNW — Study Finds CBD Could Ease Stress, Irritability Linked to Menstruation

A recent study investigated the potential effects of CBD on symptoms related to menstruation, finding that oral doses of CBD helped alleviate various symptoms such as stress, anxiety and irritability compared to participants’ initial conditions. However, depression levels remained unchanged throughout the study period. The research study marks the first of its kind to explore the impact of cannabidiol specifically on menstrual-related symptoms (MRS) and general irritability. The findings indicated notable reductions in MRS, stress, irritability and anxiety after three months of CBD use compared to baseline measurements. According to the authors, the results suggest that CBD could serve as…

MondayMar 18, 2024 9:45 am

Zoned Properties Inc. (ZDPY) Seeks to Bridge the Real Estate Shortage for the U.S. Cannabis Retail Operators

Many Landlords across the United States currently face several obstacles in leasing commercial properties to cannabis-focused tenants, on the basis of ongoing federal restrictions that impact real estate factors such as insurance, financing, and permitting Zoned Properties has sought to bridge this supply gap, with a portfolio of investment properties seeking to address the needs of the regulated cannabis industry The company has recently announced plans to refocus its investment portfolio towards direct-to-consumer retail properties, simultaneously revealing their intentions to market one of their cultivation-oriented sites for sale Zoned Properties recently revealed that 3Q2023 revenues had risen by 17.2% YoY,…

MondayMar 18, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Huge 2024 Milestone with FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria, a global innovator in drug delivery platforms, recently received FDA clearance for its HYPER-H23-1 clinical study John Docherty, President of Lexaria, has regarded this milestone as a demonstration of its patented DehydraTECH(TM) technology’s overall viability, particularly in the potential treatment of hypertension With HYPER-H23-1, Lexaria looks to build on the success of its previous human clinical studies, whose results have been overwhelmingly positive This marks a considerable milestone even as the company looks to double down on GLP-1 studies for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the…

FridayMar 08, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth

Lexaria, a global innovator in drug delivery platforms, has, since 2016, proven its patented DehydraTECH(TM) technology, asserting its superiority in improving drug bioavailability This has earned it 39 granted patents, with many pending globally DehydraTECH has a number of potential pharmaceutical applications with successful early stage results in hypertension, diabetes and weight loss and many others With its focus on GLP-1 clinical studies for 2024, Lexaria looks to carve out greater market share to make 2024 its biggest year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been pushing the envelope and redefining drug delivery technology.…

MondayMar 04, 2024 9:45 am

Zoned Properties Inc. (ZDPY) Is ‘One to Watch’

Zoned Properties in January 2024 acquired an investment property in Chicago and signed a long-term lease agreement for Justice Cannabis Co. to operate a retail dispensary there The company reported revenues of $720,450 for the quarter ended September 30, 2023, compared to $614,988 for the same quarter in 2022, an increase of 17.2% Zoned Properties reported net income of $114,523 for the September 2023 quarter, compared to a net loss of $77,328 for the same quarter a year earlier The company continues to build out its proprietary cannabis technology platform, REZONE, in preparation for commercial launch Zoned Properties in August…

TuesdayFeb 27, 2024 11:15 am

Astrotech Corp. (NASDAQ: ASTC) Reports 512% Jump in YTD Revenue

Astrotech reported financial results for the quarter ended December 31, 2023, recording year-to-date revenue of $1,540,000 The company attributed the growth to the successful fulfillment of two significant purchase orders for the TRACER 1000(TM), the world’s first mass spectrometer-based explosive trace detectors (“ETD”), to customers in Romania Astrotech is focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries 1st Detect Corp., AgLAB Inc., Pro-Control Inc., and BreathTech Corp. The company and its subsidiaries are positioned to capitalize on burgeoning markets, including the global mass spectrometry market, expected to grow from an estimated $6.77 billion in…

TuesdayFeb 27, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering

Lexaria, a global innovator in drug delivery platforms, just announced $3.6 million in gross proceeds from its registered direct offering priced at the market The proceeds will go to critical R&D studies, patent, and legal costs, as well as general working capital purposes This is timely, given Lexaria’s resolve to double down on GLP-1 investigations for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the registered direct offering for the purchase and sale of 1,558,443 shares of common stock at a purchase price of $2.31 – at the market under…

TuesdayFeb 20, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D

Lexaria, a global innovator in drug delivery platforms to enhance bioavailability, announced recently that it will focus on GLP-1 applications for diabetes and weight loss for the 2024 calendar year Chris Bunka, Lexaria’s CEO, has expressed his confidence in the company’s direction, reiterating the intention to demonstrate the superior performance of GLP-1 drugs processed with its patented DehydraTECH(TM) technology The company looks to build on the success of the early-stage results achieved in 2023, and looks to embark on two human pilot studies, a multi-arm 12-week animal chronic study, a human chronic weight-loss and diabetes study, as well as a…

FridayFeb 16, 2024 9:00 am

Software Effective Solutions Corp. (SFWJ) Experts Work with Partners, Customers to Meet Impressive Market Growth

Research forecasts global medical marijuana space will see CAGR of 22.32% over the next decade Several key factors contribute to double-digit growth MedCana has assembled a team of pharmaceutical scientists who are some of the world’s most respected chemists Recent forecasts for the global medical marijuana sector indicate significant growth, a trend that Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is paying close attention to. A global infrastructure and holding company in the cannabis industry, MedCana is on a mission to become the world’s premier resource for pharmaceutical cannabis products. The recent ResarchAndMarket.com article reported that the global medical marijuana…

News and publishing service for cannabis related companies

Contact us: 512.354.7000

Category: Uncategorized